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Cancer treatment, today, consists of surgery, chemotherapy, radiation, and most recently 
immunotherapy. Combination immunotherapy-radiotherapy (CIR) has experienced a 
surge in public attention due to numerous clinical publications outlining the reduction 
or elimination of metastatic disease, following treatment with specifically ipilimumab 
and radiotherapy. The mechanism behind CIR, however, remains unclear, though it is 
hypothesized that radiation transforms the tumor into an in situ vaccine which immu-
notherapy modulates into a larger immune response. To date, the majority of attention 
has focused on rotating out immunotherapeutics with conventional radiation; however, 
the unique biological and physical benefits of particle irradiation may prove superior in 
generation of systemic effect. Here, we review recent advances in CIR, with a particular 
focus on the usage of charged particles to induce or enhance response to cancerous 
disease.
Keywords: immunotherapy, particle therapy, proton, carbon, abscopal
introdUCtion
The traditional approach to cancer treatment has primarily consisted of three central modalities: 
surgery, radiation, and chemotherapy, the first two indicated for management of gross, macroscopic 
disease and the latter to target microscopic and systemic disease. Advances in biomolecular under-
standing of cancer has lead to enhanced focus on the role of the immune system in clearing disease, 
and today, modulation and enhancement of the immune system, immunotherapy, has emerged as 
the fourth pillar of cancer management.
Combination immunotherapy–radiotherapy (CIR) experienced a surge in public attention with 
publication of numerous clinical accounts of metastatic disease remission following combina-
tion treatment with radiotherapy and ipilimumab, a cytotoxic T-lymphocyte antigen 4 (CTLA-4) 
inhibitor (1–3). Preclinical and clinical investigations exploded soon thereafter; a search for “radia-
tion +  immunotherapy” on http://ClinicalTrials.gov in December 2016 yielded 323 results. The 
mechanism behind CIR remains unclear, though consensus may be building for radiation potentiat-
ing an immune response to a tumor, forming an in situ vaccine that, with proper immune checkpoint 
modulation, can amplify the immune response systemically through blood and lymph, overcoming 
tumor microenvironment immunosuppression (4). As such, CIR is increasingly considered one of 
the most promising strategies to defeat cancer.
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FiGUre 1 | Comparison of the dose distribution for carbon ion and 
X-rays. Panel (a) shows the physical profile of a single peak compared to a 
typical photon irradiation; in panel (B), the resulting profile of a biologically 
effective dose obtained with a Spread-Out Bragg Peak. Courtesy of Dr. Scifoni, 
Trento Institute for Fundamental Physics and Applications (TIFPA-INFN).
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Here, we review recent advances in CIR, with a particular 
focus on the usage of charged particles to induce or enhance 
response to cancerous disease.
radiotHerapy
Though innumerable immunotherapeutics are in testing, radia-
tion therapy worldwide has largely used a single type, X-ray 
irradiation. This consists of an external beam of radiation 
delivered directly to target tumor tissue, producing a generally 
uniform dose that decreases slightly from body entrance to 
exit, irradiating target tumor and healthy tissue equivalently. To 
avoid unnecessary healthy-tissue damage, dose is delivered in 
multiple fractions, with healthy tissue self-repairing while DNA 
damage accumulates in the generally repair-deficient tumor. 
Further, the beam is often delivered from multiple angles or in 
an arc, collating dose in the tumor while minimizing total radia-
tion exposure to healthy tissue. Conventional X-radiotherapy 
operates under a twofold mechanism. The first involves direct 
DNA damage, with energy delivered causing single-strand 
breaks and occasionally double-strand breaks in DNA; if the 
cell is unable to repair, it will undergo apoptosis or necrosis. 
Second, radiation has an indirect effect through creation of 
oxygen free-radicals in the target beam path, which lead to 
further local damage. The principle challenge of radiotherapy 
thus hinges on the inherent radioresistence of target tissue in 
relation to the radiosensitivity of surrounding normal tissue, 
and so the ability to deliver maximal target dose with minimal 
surrounding is paramount.
Particle radiotherapy (PRT) has been in various stages of 
research and development for 70 years, and today, clinical treat-
ment is available in the form of either proton or carbon-ion 
radiotherapy. PRT operates by accelerating single particles to 
high velocities and directing them toward target tissue, with 
distance traveled in tissue a function of particle energy. As 
the particle slows, the number of ionization events with its 
surrounding environment increases, resulting in a dose-release 
spike known as the Bragg Peak (Figure  1A). This results in a 
comparatively low entry dose and little-to-no exit dose com-
pared with X-ray irradiation. Smaller particles, such as proton, 
have a sharper distal dose edge but generate a slight penumbra 
due to scattering in tissue; heavier ions have a slightly higher 
exit dose due to nuclear fragmentations, with sharper lateral 
margins. To deliver target dose to the entire body of the tumor, 
the Bragg peaks are overlapped to form a spread-out Bragg 
peak (Figure  1B).
Originally, this was performed using a series of collimators 
and range filters to spread the beam, generating an excess neutron 
dose to the overall body of the target. However, recent advances 
allowed first proton and now heavy-ion beams to be actively 
scanned point-by-point across the target, eliminating excess dose 
and allowing improved dose delivery (5).
In addition to the dose-distributive benefits afforded by particle 
beams, heavy-ion beams have a high linear energy transfer (LET), 
that is, a higher amount of energy per particle transferred per unit 
distance. This increased number of ionization events delivered 
in a shorter distance interval yields an enhanced probability for 
double strand DNA breaks among other effects within a tumor 
cell; this is related to the biological damage delivered per unit 
dose by calculated comparison to an equivalent photon dose, 
and is termed the relative biological effectiveness (RBE). Original 
research in this area consisted of usage of neutron irradiation from 
the 1950s to 1970s, which demonstrated high LET but poor dose 
distribution; this lead to employment of proton, which offered 
superior dose distribution but little LET benefit. Principally 
from the 1990s, carbon-ions have been employed in Japan and 
Germany, offering both dose-distributive and LET benefits (6). 
The combination of dose-distribution benefit with an enhanced 
RBE 2 to 3× that of photon has lead to evidence that carbon-
ions, owing to the direct DNA damage mechanism they employ, 
are relatively cell-cycle and oxygenation independent, and can 
be used to treat hypoxic and radioresistant disease (7). As the 
LET value of the carbon-ion and other heavy-ion beams varies 
throughout the beam path, future developments may involve 
“painting” high-LET values to target areas, further enhancing the 
biological effect (7, 8).
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To date, radiotherapy has been thought of as a predominantly 
local treatment, with no systemic effect. However, X-irradiation 
has demonstrated involvement in both immunostimulation and 
immunosuppression (9, 10). Preclinical work has revealed that 
PRT appears to induce an identical or broader immunogenic 
response versus X-irradiation (11, 12), as well as evidence that 
carbon-ion beams induce anti-metastatic and anti-angiogenic 
effects.
CanCer iMMUnosUrVeiLLanCe
In addition to the direct effects of radiation, surgery, and chemo-
therapy, the immune system plays a distinct role in recognizing 
and destroying cancer cells, as well as in clearing and repairing 
the damage caused by the first three methods. Burdet and Thomas 
first hypothesized that the immune system can recognize and 
eliminate transformed cells when they first occur, thus strongly 
decreasing cancer incidence than may be seen in immuno-
incompetent individuals; though this hypothesis was abandoned, 
today evidence clearly supports it (13). Immunodeficient HIV 
patients have a noted increase in cancer incidence (14); cancer 
incidence appears to return toward baseline with fast adminis-
tration of therapy (15). Choy et al. suggested that highly active 
antiretroviral therapy (HAART) improved glioblastoma survival 
in HIV+ patients, suggesting that HAART-enabled repopulation 
of the immune system’s white blood cell population improved 
outcomes, even in glioblastoma, which is largely protected from 
immune system interaction due to the blood–brain barrier (16).
This initial immunosurveillance hypothesis has come to be 
embodied by the “three E’s” of cancer development. The first is 
elimination. Cancer cells present new surface antigens that are 
recognized by the immune system as exogenous or “not-self,” 
leading to cancer cell recognition by antigen-presenting cells 
(APCs), immune activation, and facilitation of cancer cell elimi-
nation by CD8+ cytotoxic T-lymphocytes (CTLs). This generates 
a microevolutionary pressure in which only those cells able to 
avoid non-self antigen presentation, or to suppress the immune 
response in their environment, survive. The immune system 
thus shapes tumor progression, and this process is termed 
immunoediting (17). Avoidance of self-reporting to CTLs 
involves downregulation or inactivation of major histocompat-
ibility complex I (MHC-I) antigen processing and presentation. 
Tolerogenic factors are further released by the cell to diminish 
surrounding CTL activity, modifying intratumoral dendritic 
cells (DCs), and recruiting and enhancing activity of regulatory 
DCs and T-cells (Treg), in addition to myeloid-derived sup-
pressor cells (MDSCs) and tumor-associated macrophages. The 
result is an environment of diminished T-cell activity. This point 
is termed equilibrium, and occurs when elimination and replica-
tion of cancer cells is held in check, with the tumor unable to 
expand freely; the cells further accumulate mutations to enhance 
growth, immunosuppress the local environment, and to achieve 
metastatic potential. Finally, escape occurs, in which the growth 
of the cancer outpaces, through suppression and evasion, the 
immune system (18).
Treg cells may otherwise be termed suppressor T-cells, and are 
a subpopulation that serve to maintain self-tolerance and prevent 
autoimmune disease through suppression of active T-cells. They 
are formed in response to TGFβ expression, which further serves 
to maintain them. However, Treg immunosuppressive activity 
can be co-opted by tumors to contribute to their evolution toward 
escape; patients with a high Treg infiltration are known to have a 
poor prognosis (19). As these cells are considered to be contribu-
tory in the development of cancer, they form distinct targets in 
the tumor microenvironment. However, they are radioresistant, 
attenuating response and contributing to increased radioresist-
ance following irradiation, while also increasing in number.
Myeloid-derived suppressor cells are further immunosup-
pressive, reducing the activation of other white cell populations. 
They serve to release the inflammatory cytokine prostaglandin 
E2 (PGE2), supporting tumor growth and cancer repopulation, 
while protecting tumor cells from apoptosis. PGE2 increases 
following irradiation, and its release is tied to the LET of the 
radiation employed, as well as oxygen concentration (20).
Radiation has been demonstrated as both immune-
stimulating as well as immune-suppressive. This balance can be 
shifted using immunotherapeutics. Long-term clinical results, 
principally of melanoma remission following administration 
of radiotherapy and ipilimumab (3), have demonstrated the 
potential for this combination in a clinical setting. Subtotal 
responses reveal that further work is needed to overcome exist-
ing disease resistance, as well as to prevent disease adaptation 
to the blockade.
radiation and iMMUnoaCtiVation
Radiation has a unique effect on tumor tissue, serving as a means 
by which to generate immunogenic cell death (ICD) within a 
tumor (Figure 2). Upon exposure to radiation, tumor cells present 
damage-associated molecular patterns (DAMPs), which enable 
the cell to be engulfed by APCs. These are in turn presented to 
CTLs, leading to tumor destruction. This pathway is facilitated by 
IRE1, PERK, and ATF6, which in low-stress conditions are inac-
tivated by BiP/GRP78. Following irradiation, this inactivation 
diminishes, leading to DAMP trafficking to the surface. DAMP 
response to radiation appears to be dose dependent and varies 
significantly with tumor histology and genetics.
Within the DAMPs, calreticulin (CRT), ATP, high mobility 
group box-1 (HMGB1), and type I interferons appear to play the 
major role (21, 22). When a cancer cell is undergoing ICD, 6× 
normal concentration levels of CRT are found on the surface. This 
is dependent on PERK-mediated phosphorylation of EIF2α or 
inhibition of Eif2α-specific phosphatase complex PP1/GADD34. 
With radiation, this process appears to be mediated by Erp57. 
CRT interacts with SNAREs on the cell surface, interacts with 
the TNF family, and may activate complement C1q; essentially, it 
serves as a potent dendritic cell “eat me” signal. This signal may be 
counteracted by the antiphagocytic molecule CD47, considered 
the “do not eat me” signal (23), which is ubiquitously expressed 
in human cells and overexpressed in numerous tumors. Radiation 
seems to reduce the amount of CD47, increasing the rate of cell 
phagocytosis.
High mobility group box-1 is a highly conserved nuclear pro-
tein involved with replication, and is expressed in nearly all cells. 
FiGUre 2 | radiation increases major histocompatibility complex i 
and enhances calreticulin (Crt) translocation and atp-high mobility 
group box-1 (HMGB1) release. Those signals are fundamental to activate 
dendritic cells (DC). Activated DC increase their mobility and move to the 
lymph nodes where they activate T-cells. The increase of prostaglandin E2 
(PGE2) and TGFβ could yet be counterproductive, increasing the population 
of myeloid-derived suppressor cells (MDSC) and Treg cells responsible for 
immunosuppression.
4
Ebner et al. Particle Immunoradiotherapy
Frontiers in Immunology | www.frontiersin.org February 2017 | Volume 8 | Article 99
It serves as an immunoactivating cytokine and DAMP when 
released by necrotic cells following ablative radiotherapy, acti-
vating DCs through toll-like receptor 4 (TLR4) (24). Inhibition 
of HMGB1–TLR4 interaction leads to earlier relapse in breast 
cancer patients, while HMGB1 levels following chemo-irradia-
tion were predictive for survival, perhaps due to their effects on 
the proliferation of CTLs. Similarly, ATP and Interferon γ are 
released following irradiation in cells consequently undergoing 
ICD; ATP binds to P2Y2 and P2X7 purinergic receptor on mac-
rophages and DCs, leading to activation of the DC inflamma-
some, secretion of IL-1β, and leading to inflammatory cytokine 
production. Meanwhile IFNγ increases following irradiation 
and enhances the level of APM-components, ultimately pro-
ducing an increase of the MHC-I complex. Other mechanisms 
for immunoactivation secondary to radiation therapy include 
MHC-I activation via the CERAMIDE pathway, with VEGF-
induced damage triggered by ASMase responsible for MHC-I 
enhancement (25). Less directly, blockage of type-I interferons 
or modification of TLR3 signaling stopped ICD in target tumors, 
suggesting a mechanism at work. Heat shock proteins 70 and 90 
(Hsp70, Hsp90) are both directed to the cell surface during ICD, 
with released Hsp70 serving as a DAMP. Further, any DAMPs 
produced during ICD, regardless of radiation, also play a role in 
the downstream effects of ablative irradiation.
radiation and iMMUnosUppression
However, radiation is a two-sided coin, comprising not only 
immune activation but also suppression. The effect of radiation 
on the immune system itself is not well understood, with local 
dendritic and T-cells also being exposed to irradiation during 
treatment. Merrick et al. found that human myeloid DCs were 
very resistant to radiation-induced apoptosis and maintained 
their migratory and phagocytic capacities following radiation 
(26). However, irradiated DCs were less effective at activating 
lymphocytes and, when mature, were less able to produce immu-
noactivating IL-12 compared to control. As such, DC irradiation 
in vitro and, potentially, in vivo, may diminish immunoactivation 
and comparatively suppress immune response overall. This is in 
addition to any innate local immunosuppression caused by the 
naïve tumor; Merrick et al. thus suggested that irradiation of DC 
could shift the delicate balance from tumor regression to one of 
tumor expansion and escape. Patients exhibiting immunosup-
pression have been found to require higher radiation dose for 
local control (27).
More directly, upregulation of PD-L1 in tumor cells has been 
seen following irradiation, which Park and colleagues demon-
strated can limit generation of an abscopal effect, in which distant 
disease regression is noted (28). Melanoma was injected into the 
hindlimbs of PD-1-deficient C57BL/6 mice and compared to 
wild-type following treatment of one limb with SABR; mice defi-
cient in PD-1 saw a fivefold reduction in their untreated tumor. 
This suggests activity of PD-1 as an anti-abscopal marker. PD-1 
operates by downregulating the immune system and promoting 
self-tolerance, inducing apoptosis in T-cells and overall con-
tributing to generation of an immunosuppressive environment. 
Blockade of PD-1 allows systemic expansion of T-cells, increasing 
tumor infiltration. Consequently, blockade of PD-1 may allow for 
better triggering of the abscopal effect.
Further, radiation increases the amount of PGE2 cytokine 
(20), which not only contributes to the Phoenix Rising effect, in 
which surviving distant disease becomes more aggressive and fast 
growing following local treatment, but also increases the popula-
tion of MDSCs and contributes to a shift of T-cells to Treg cells. 
This contributes to the immunosuppressive environment.
TGFβ is also released following irradiation, leading to 
immune suppression by increasing the ratio of Treg cells. It 
is unclear precisely what role TGFβ serves, though in mice it 
appears to be age-related. Co-activation with IL-6 produced 
by mature DCs appears to be an important parameter to shift 
TGFβ to immunoactivation over suppression (29). TGF-β is also 
implicated in B-lymphocyte proliferation and NF-κB inhibition. 
It increases the apoptosis of immature B-lymphocytes.
The decision to refrain from or to undergo ICD plays a major 
role in development of immunosuppression or immunoactiva-
tion. Following damage, cells may attempt self-repair or become 
apoptotic. Langerhans cells in the skin, following UV irradiation, 
are able to induce Treg cells and avoid immune self-destruction 
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even if they are expressing foreign “non-self ” antigens. This is 
thought to prevent autoimmune reactions in the skin, but the 
exact mechanism is unclear (30). However, this may be co-opted 
by tumors, facilitating escape from immune detection. Similar 
mechanisms exist: inhibition of macrophages, DCs, or T-cells can 
further be accomplished through the release of cytokines. IL-10, 
for instance, interferes with DC maturation by blocking T-cell 
activation.
iCd and radiotHerapy
The irradiation and destruction of local immune system cells in 
theory may contribute to immunosuppressive shift. In this vein, 
particle irradiation may be beneficial due to a reduced integral 
dose and overall reduced irradiated volume compared with pro-
ton, limiting unnecessary destruction of lymphocytes (31, 32). 
Photon radiotherapy induces ICD in a dose-dependent manner 
via CRT translocation, and HMGB1 and ATP release (33), which 
are necessary for radiation treatment success (34). Depending 
in part on dose and type of radiation delivered, varying types of 
induced cell death may result: apoptosis, necrosis, mitotic catas-
trophe, necroptosis, or autophagy. When these processes occur 
with the translocation of CRT, HMGB1, and ATP release, or the 
dispersion/release/translocation of other immune-stimulating 
antigens from dying cells into the surrounding milieu, this leads 
to immune system activation and may be termed immunogenic 
cell death (35).
Traditionally, cell killing is ascribed to four basic prin-
ciples, termed the “4 R’s of Radiobiology”: reassortment, 
reoxygenation, repair, and repopulation. Recent discussion has 
lead to the suggestion that ICD may be considered the fifth 
radiobiological principle, due to induction of immune system 
activation and potential generation of a systemic antitumor 
effect (36). Though the local consequences of irradiation in 
a tumor are readily apparent, with development of ICD due 
to direct irradiation effects, as well as induction of immune 
system response in the local environment, recent attention has 
turned to what role ICD may play in the generation of systemic 
effects. It is proposed that immunoactivation may extend 
beyond the local tumor, facilitating a system-wide antitumor 
response. Circulating levels of cytokines have been found fol-
lowing radiotherapy, with prostate adenocarcinoma patients 
and head and neck cancer patients both having detectable 
levels of inflammatory and/or fibrogenic factors in circulation 
following radiotherapy (37).
CoMBination iMMUnotHerapy and 
radiotHerapy
Usage of CIR to induce systemic regression of cancerous 
disease is hoped to revolutionize cancer treatment, allowing 
generation of bystander or abscopal effects, signifying regional 
or distant antitumor effect, respectively. Though the precise 
mechanism remains unknown, radiotherapy is thought to 
convert an individual tumor into an in  situ vaccine, after 
which it serves as a way station for immune system activa-
tion, amplification, and proliferation in targeting systemic 
disease (34). This vaccination effect has been seen in colon 
cancer (38). The abscopal effect has been known for decades 
to occur with radiotherapy alone, although it was notably rare 
(39, 40). Clinical abscopal effects remained mechanistically 
elusive, until in 2004 when Demaria and colleagues suggested 
that it is immune-moderated (41). With the advent of modern 
immunotherapeutics, which can be administered to preserve, 
amplify, and regionosystemically expand these responses, the 
possibility of inducing a controlled abscopal effect is nearing 
reality. Mechanistically, the existence of radiotherapy-only 
abscopal effects suggest that the driving agent of the effect 
either occurs spontaneously or is secondary to radiation in 
a small proportion of patients, respectively. Immunotherapy 
thus aims to extend the potential for abscopal effect generation 
to a wider population.
Case reports have been seen in a variety of tumor histologies, 
though the most replicable thus far appear to focus on combina-
tion radiotherapy and CTLA-4 inhibition (via ipilimumab) in 
melanoma (1–3, 42). Melanomas (30–40%) have NY-ESO-1 
and may thus be susceptible to ipilimumab. In one case, a 
patient was treated with ipilimumab and kept on maintenance. 
Palliative radiotherapy was applied to a paraspinal mass, with 
ipilimumab again delivered a month following. Two months 
thereafter, widespread disease regression was noted, with mini-
mal stable disease 6 months later. Post-radiotherapy showed a 
30-fold increase in antibodies against NY-ESO-1 protein (3). 
Addition of PD-1 blockade has yielded a similar abscopal effect 
against melanoma and RCC (37). A phase I trial of combina-
tion therapy in melanoma found increased PD-L1 expression 
following treatment, with less than 20% of patients developing 
abscopal-like reactions; blocking PD-L1 was suggested. DCs 
treated ex vivo with different activators and modifiers and then 
delivered intravascularly or intratumorly, in combination with 
radiation, have also demonstrated good results in multiple 
studies, and may be promising as a treatment amplification 
option. As DCs serve as the primary activators of the local 
immune response, direct DC injection is thought to improve 
the likelihood of overcoming environmental immunosuppres-
sive effects.
Unfortunately, the precise mechanism behind clinical induc-
tion of CIR-mediated disease remission has yet to be under-
stood and thus is difficult to replicate on a population basis, 
forming the central challenge behind clinical treatment with 
immunoradiotherapy. Due to the microevolutionary nature of 
cancer treatment and heterogeneity of tumors, any individual’s 
tumor ideally will be targeted with disease-, histology-, and 
perhaps genetic-level precision, as cells surviving initial treat-
ment can expand unheeded. Mechanistic understanding of CIR 
is needed.
partiCLe CoMBination tHerapy
Particles have been theorized to increase the advantages and 
utility of CIR. Particles appear to demonstrate higher antitumor 
effects versus photon irradiation, with reports that they are more 
effective in reducing metastasis (43), while reducing or prevent-
ing local recurrence (44, 45).
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The immunogenicity of radiation may correlate to the density 
of irradiation, with enhanced efficacy seen with high-LET, densely 
ionizing radiation in cell cultures (12, 46). Among other pathways, 
high LET radiation appears to increase the CERAMIDE pathway 
more efficiently than low LET X-ray (47). Across multiple tumor 
cell lines, protons mediated CRT translocation to the cell surface, 
increasing cross-priming and sensitivity to CTLs (11). This may 
be enhanced with more densely ionizing heavy ions, such as 
oxygen or carbon.
In mouse studies, in combination with DC injection, the 
carbon-ion beam correlated with a greater amount of immune 
activation (48). Though DC injection has been found promising 
with photon trials, as carbon-ions are generally used to treat 
deep-seated tumors, intratumoral dendritic cell injection may 
not be feasible with many carbon patients. Alternate delivery 
methods and/or alternate in  situ DC amplification methods 
may be necessary (48, 49). Animal studies involving immuno-
therapeutic agents combined with carbon-ion irradiation are 
underway.
Carbon-ions have been linked to induction of an abscopal 
effect in combination with immunotherapy (48). There has 
been a theoretical response to carbon seen with pancreatic 
cancer patients, as well as abscopal-like effects seen with the 
carbon-ion beam. An 85-year-old patient received 50.4  Gy 
(RBE) in 12 fractions for an ascending colon carcinoma, with 
mediastinal lymph node metastases resolving 6 months follow-
ing carbon-ion radiotherapy. Whether this is due to ablative 
dose delivery afforded by the carbon-beam, or an immunogenic 
effect secondary to the usage of high-LET radiation, remains 
to be elucidated.
UnKnoWns and tHe FUtUre
To this end, numerous avenues of radiotherapy and their effect 
on the systemic immune system remain to be clarified. Though 
combination reactions have been clinically demonstrated, they 
remain rare, with clinical trials commonly reporting maximal 
systemic disease regression rates of 20% or less. Tumors are 
now known to be heterogeneous, and so therapy that eliminates 
disease, and does not simply select for resistant disease, must 
be employed. Which combinations of immunotherapeutics 
are indicated in what diseases and histologies, the (epi)genetic 
profiles of those diseases, as well as variables such as whether 
surgery or chemotherapy are performed, timing and dose, 
as well as radiation usage, radiation type, dose, fractionation, 
and more, all may play a role in the delicate balance between 
immunoactivation and immunosuppression (50). Conventional 
fractionation regimens tend to settle at 2  Gy per fraction; 
hypofractionated fractions can deliver 20+ Gy per fraction, and 
appear to lead to greater immunoactivation. The reasoning for 
this may lie in the effect of fractionation on local lymphocytes: 
notably radiosensitive, lymphocytes invade the damaged tumor 
space, only to be repeatedly irradiated over the treatment period. 
Following classical irradiation protocols, the level of circulating 
lymphocytes in peripheral blood is notably low (51). Reduced 
fractionation may result in less peripheral lymphocyte death, 
and thus may serve to diminish systemic response in comparison 
with hypofractionation. Increasing dose would increase local 
CRT translocation, as well as HMGB1 and ATP release.
Nonetheless, in vitro studies suggest conventional fractiona-
tion is superior to hypofractionation in terms of activating the 
immune system. Rubner and colleagues found that fractionated 
radiation was better able to induce release of Hsp70, leading to 
DC maturation (52). Kulzer and colleagues similarly found that 
classical RT may better enable the tumor to serve as immuno-
activation point, leading to a stronger immune response. They 
compared classical RT with single-dose protocols, finding 
elevated levels of immunoactivating cytokines IL-12p70, IL-8, 
IL-6, and TNF-α (53).
It has been demonstrated that different types of radiation are 
differentially efficient on differing tumor types, with some studies 
indicating cases where particle irradiation was less effective or 
equal to photon (54, 55). Modulation of dose and fractiona-
tion remain unclear: in an animal model, stereotactic ablative 
body radiotherapy was demonstrated to be superior to classic 
RT fractionation, while in  vitro evaluation suggested that for 
immune activation, classical fractionation was superior. Tsai and 
colleagues found differences in gene expression between classical 
and single-dose protocols, with robust gene induction found in 
the fractionated protocol (56). These unknowns will require study 
in the future.
Technological availability is reaching the point where different 
tumor types can be targeted with different ions, depending on 
their suitability. Heavy-ion facilities are being built rapidly in 
the world, with 2 in Europe, 6+ in Asia, and plans to construct 
2+ in North America. Switching from one ion to another takes 
only minutes, and preliminary evidence suggests unique benefits 
offered by proton (sharp distal dose), as well as carbon and oxygen 
(sharp lateral doses and high LET) (57). Helium and lithium may 
soon be employed; it is possible immunoactivation may respond 
differently with ion type, and so comprehensive studies of these 
combinations will be needed.
Combination immunotherapy and radiotherapy offers a 
powerful modality for the treatment of cancer, and for the first 
time in cancer treatment, a potential therapy resulting in total 
remission of stage IV, distant disease, may be mechanistically 
understood. Innumerable factors play a role: the specific targets 
of immunotherapeutics, ex vivo modulation and reimplantation 
of immunoactivating cells, surgery, chemotherapy, radiation, 
and the dose, type, and timing of all these treatments. It is hoped 
that with careful understanding of the mechanisms involved, for 
the first time the clinical view of distant, stage IV illness may be 
shifted from “palliative” to “curative.”
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